Pre-clinical models of genetically heterogeneous multiple myeloma reveal mechanisms of immune escape and predict clinical immunotherapy outcomes

被引：0

作者：

Larrayoz, Marta ^{[1
]}

Garcia-Barchino, Maria J. ^{[1
]}

Celay, Jon ^{[1
]}

Etxebeste, Amaia ^{[1
]}

Jimenez, Maddalen ^{[1
]}

Perez, Cristina ^{[1
]}

Ordonez, Raquel ^{[1
]}

Cobaleda, Cesar ^{[2
]}

Chesi, Marta ^{[3
]}

Bergsagel, Leif ^{[3
]}

Rodriguez-Otero, Paula ^{[4
]}

Takahashi, Satoru ^{[5
]}

Katz, Samuel G. ^{[6
]}

Walensky, Loren D. ^{[7
]}

Ruppert, Shannon M. ^{[8
]}

Lasater, Elisabeth A. ^{[8
]}

Amann, Maria ^{[9
]}

Lasarte, Juan J. ^{[1
]}

Kurilovich, Anna ^{[10
]}

Cerchietti, Leandro ^{[11
]}

Agirre, Xabier ^{[1
]}

San-Miguel, Jesus ^{[12
]}

Paiva, Bruno ^{[12
]}

Prosper, Felipe ^{[13
]}

Martinez-Climent, Jose A. ^{[1
]}

机构：

[1] Univ Navarra, Pamplona, Spain

[2] Univ Autonoma, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, Madrid, Spain

[3] Mayo Clin, Rochester, MN USA

[4] Clin Univ Navarra, CIMA, IDISNA, CIBERONC, Navarra, Spain

[5] Univ Tsukuba, Fac Med, Tsukuba, Ibaraki, Japan

[6] Yale Sch Med, New Haven, CT USA

[7] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Genentech Inc, San Francisco, CA USA

[9] Roche Innovat Ctr Zurich, Zurich, Switzerland

[10] Bostongene Corp, Waltham, MA USA

[11] Weill Cornell Med, New York, NY USA

[12] Clin Univ Navarra, Inst Invest Sanitaria Navarra IDISNA, Ctr Invest Med Aplicada CIMA, CCUN,CIBER ONC, Pamplona, Spain

[13] Clin Univ Navarra, Pamplona, Spain

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-033

引用

页码：S19 / S20

页数：2

共 50 条

[41] The innate immune system and neurogenesis as modulating mechanisms of electroconvulsive therapy in pre-clinical studies
Giacobbe, Juliette
Pariante, Carmine M.
Borsini, Alessandra
JOURNAL OF PSYCHOPHARMACOLOGY, 2020, 34 (10) : 1086 - 1097
[42] Physical exercise and synaptic protection in human and pre-clinical models of multiple sclerosis
Federica Azzolini
Ettore Dolcetti
Antonio Bruno
Valentina Rovella
Diego Centonze
Fabio Buttari
Neural Regeneration Research, 2024, 19 (08) : 1768 - 1771
[43] Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation
McMillin, Douglas W.
Delmore, Jake
Negri, Joseph
Ooi, Melissa
Klippel, Steffen
Miduturu, Chandrasekhar V.
Gray, Nathanael S.
Richardson, Paul G.
Anderson, Kenneth C.
Kung, Andrew L.
Mitsiades, Constantine S.
PLOS ONE, 2011, 6 (07):
[44] Using the canine microbiome to bridge translation of cancer immunotherapy from pre-clinical murine models to human clinical trials
Kleber, Kara T. T.
Iranpur, Khurshid R. R.
Perry, Lauren M. M.
Cruz, Sylvia M. M.
Razmara, Aryana M. M.
Culp, William T. N.
Kent, Michael S. S.
Eisen, Jonathan A. A.
Rebhun, Robert B. B.
Canter, Robert J. J.
FRONTIERS IN IMMUNOLOGY, 2022, 13
[45] Potent activity of a novel, irreversible inhibitor of the ubiquitin-proteasome pathway against pre-clinical models of multiple myeloma.
Kuhn, DJ
Voorhees, PM
Strader, JS
Shenk, KD
Sun, CM
Demo, SD
Bennett, MK
Orlowski, RZ
BLOOD, 2005, 106 (11) : 452A - 452A
[46] Isatuximab based combinations induce potent tumor growth inhibition in pre-clinical models of multiple myeloma and acute lymphocytic leukemia
Zhu, Chen
Nicolazzi, Celine
Van de Velde, Helgi
Wiederschain, Dmitri
Sidhu, Sukhvinder
Chiron, Marielle
CANCER RESEARCH, 2020, 80 (16)
[47] Targeted radiotherapy for patients with multiple myeloma: Results of pre-clinical evaluation of candidate antibodies.
Orchard, KH
Cooper, M
Mehta, A
Potter, M
Wijdenes, J
Borchardt, P
Quadri, S
Goldman, J
Samson, D
Apperley, J
Buscombe, J
Hilson, A
Myers, M
Amlot, P
Begent, R
Prentice, HG
BLOOD, 1999, 94 (10) : 302B - 302B
[48] Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Schoenfeld, Kurt
Zuber, Chantal
Pinkas, Jan
Haeder, Thomas
Bernoester, Katrin
Uherek, Christoph
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
[49] Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities
Botta, Cirino
Gulla, Annemaria
Correale, Pierpaolo
Tagliaferri, Pierosandro
Tanssone, Pierfrancesco
FRONTIERS IN ONCOLOGY, 2014, 4
[50] Strengths andWeaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy
Barutello, Giuseppina
Rolih, Valeria
Arigoni, Maddalena
Tarone, Lidia
Conti, Laura
Quaglino, Elena
Buracco, Paolo
Cavallo, Federica
Riccardo, Federica
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (03)

← 1 2 3 4 5 →